Evolocumab vs Alirocumab — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

PCSK9 Inhibitor

Evolocumab

Brand: REPATHA

First FDA approval: 2018-10-09

PCSK9 Inhibitor

Alirocumab

Brand: Praluent

First FDA approval: 2015-07-24

Lowest NADACAcquisition cost floor across all NDCs

$281.24Per unit

$258.06Per unit

Average NADACAcross all dosage forms and strengths

$281.60Up to $281.95

$258.11Up to $258.16

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$3.25BFull year

$494.4MFull year

Part D claims (CY24)Total fills, all strengths

3.7M931K beneficiaries

647K161K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$890Per claim, all NDCs

$765Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

509Substantial friction

86Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

104Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only